Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:neurodegenerative_diseases
|
| gptkbp:affects |
gptkb:movement
both genders |
| gptkbp:associated_with |
CAG repeat expansion
neurodegeneration |
| gptkbp:can_cause |
gptkb:depression
anxiety weight loss mood swings dysphagia |
| gptkbp:can_lead_to |
gptkb:death
caregiver burden |
| gptkbp:caused_by |
gptkb:Genetics
|
| gptkbp:diagnosis |
genetic testing
family history clinical evaluation neurological examination |
| gptkbp:first_described_by |
gptkb:George_Huntington
|
| gptkbp:has_a_focus_on |
support groups
public awareness campaigns research funding fundraising efforts advocacy organizations |
| https://www.w3.org/2000/01/rdf-schema#label |
Huntington's chorea
|
| gptkbp:inherits_from |
autosomal dominant
|
| gptkbp:is_associated_with |
increased risk of suicide
|
| gptkbp:is_characterized_by |
cognitive decline
involuntary movements emotional disturbances |
| gptkbp:is_common_in |
African populations
Asian populations people of European descent |
| gptkbp:is_linked_to |
motor dysfunction
neurotransmitter imbalances cognitive dysfunction brain atrophy |
| gptkbp:is_managed_by |
medications
physical therapy occupational therapy speech therapy |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:onset_age |
30 to 50 years
|
| gptkbp:player_development |
gradual
|
| gptkbp:prevalence |
approximately 5-10 per 100,000
|
| gptkbp:research |
gene editing techniques
neuroprotective strategies potential biomarkers |
| gptkbp:research_focus |
gptkb:gene_therapy
|
| gptkbp:symptoms |
gptkb:Chocobo
cognitive decline psychiatric disorders |
| gptkbp:treatment |
symptomatic management
antidepressants antipsychotics mood stabilizers |
| gptkbp:bfsParent |
gptkb:Huntington_disease
|
| gptkbp:bfsLayer |
8
|